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Objectives: Gene therapy may provide a means of modifying factors that
contribute to the development of pathologic processes in transplanted
lungs. Experiments were designed to study the feasibility of adenovirus-
mediated gene transfer by way of the airways to the transplanted lung.
Methods: Orthotopic left lung transplantation (Lewis to Lewis rats) was
performed on four groups of animals. 300 ml of adenovirus solution
encoding for b-galactosidase was infused into the left bronchus of donor
rats at viral concentrations of 108 pfu/ml (n 5 5), 109 pfu/ml (n 5 6), and
1010 pfu/ml (n 5 6), and the lung was ventilated for 5 minutes. Controls
(n 5 6) received medium only. Seven days after transplantation, native and
transduced, transplanted lungs were harvested. Sections of lung were fixed
and stained with a solution of X-Gal (5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside) and staining was evaluated for distribution by cell type
and intensity. Results: b-Galactosidase expression was absent in the control
group and in the native lungs. Two of five lungs in the 108 group expressed
b-galactosidase, but in a limited distribution and intensity. All six lungs in
the 109 group and five of six lungs in the 1010 group expressed b-galacto-
sidase. The distribution and intensity of b-galactosidase expression ranged
from only a few cells staining per slide to up to 75%. Pneumocytes were the
most frequently stained cell type followed by alveolar macrophages. Con-
clusions: Gene transfer to the transplanted lung via the bronchial route is
feasible and offers a novel technique to modify pathologic processes in the
transplanted lung. (J Thorac Cardiovasc Surg 1998;115:638-43)
Lung transplantation is an accepted treatment forselected patients with end-stage pulmonary dis-
ease. Current survival is 70% at 1 year and 45% at 5
years.1 Although early results have improved after
lung transplantation, significant long-term attrition
occurs. Postoperative complications include acute
and chronic rejection, infection, and the side effects
of immunosuppressive treatment.
Emerging gene therapy techniques provide a po-
tential novel method of controlling these processes
at a molecular level. Adenoviral-mediated gene
transfer has been used to obtain efficient gene
transfer and expression in different cells, tissues, and
organs, including transplanted hearts2-4 and recently
to lung grafts by way of the pulmonary artery.5 One
advantage of adenoviral vectors for gene transfer is
the ability to transduce nonreplicative cells. Adeno-
viral vectors can be grown to high titer and are
usually not incorporated into the host cell genome,6
thus avoiding the risk of insertional mutagenesis.
Disadvantages of adenoviral-mediated gene transfer
include cytotoxicity, limited duration of expression,
and the inability to administer a second dose be-
cause of an immune response.6
In nontransplanted lungs, adenovirus-mediated
gene transfer by way of the airways has been report-
ed.7, 8 In contrast, gene transfer to the transplanted
lung by way of the airways has not been reported.
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The addition of a major operation and cold ischemia
to the organ make observations obtained under
nontransplant conditions unreliable in the setting of
organ transplantation. We hypothesized that adeno-
virus-mediated gene transfer to lung grafts might be
feasible using a bronchial route of administration.
Methods
Animals. Forty-six inbred Lewis rats (Harlan Sprague
Dawley, Inc., Indianapolis, Ind.), weighing 250 to 320 gm
were used in the experiments. Animal care was conducted
in accordance with the “Principles of Laboratory Animal
Care” formulated by the National Society for Medical
Research and the “Guide For the Care and Use of
Laboratory Animals” prepared by the National Institutes
of Health (NIH Publication No. 86.23, revised 1985).
Adenovirus vector. A replication defective adenovirus
vector encoding for b-galactosidase (b-gal) under the
control of the cytomegalovirus promoter (AdCMVLacZ,
a kind gift from James Wilson, Institute for Human Gene
Therapy, University of Pennsylvania) was used as the
reporter gene. The adenoviral vector is a first-generation,
serotype 5, E1-E3 deleted vector.9 The recombinant virus
was propagated in 293 cells and then isolated and purified.
Viral titers were determined by plaque assay and ex-
pressed as plaque-forming unit per milliliter (pfu/ml).
Three hundred microliters of the viral solution (diluted in
2% fetal calf serum in 199 medium) was used in all viral
transductions. Control animals received the same volume
of medium. The volume for bronchial infusion was deter-
mined in preliminary experiments in which medium
stained with Evans blue dye was infused into the left
bronchus until the left lung became fully stained, and the
injected volume was measured.
Experimental groups. Donor rats were divided into
three groups receiving different concentrations of the viral
solution. The first group (n 5 5) received a viral dose of
1 3 108 pfu/ml, the second group (n 5 6) 1 3 109 pfu/ml,
the third group (n 5 6) 1 3 1010 pfu/ml. A fourth group
(n 5 6) of transplanted rats received medium only and
served as control animals. The viral administration and
transplantation was first accomplished in four animals in
the l09 pfu/ml group followed by four in the 1010 group,
four in 108 group, and four control animals. After this, the
remaining animals were transplanted in random order.
Gene transfer and transplantation. After anesthesia,
the donor rat was intubated and ventilated (Harvard
Rodent Ventilator, Harvard Apparatus Co., Inc., S.
Natick, Mass.). A median sternotomy was performed to
expose the lungs. After dissection of the hilum, the rat was
given 100 units of aqueous heparin injected into the
inferior vena cava. The tidal volume was reduced to 50%
and the right bronchus occluded. The viral solution (300
ml) was instilled in the left bronchus without pressure. The
lung was ventilated for 5 minutes to allow distribution of
virus. The clamp on the right bronchus was released and
the right atrium was opened. Twenty milliliters of pneu-
moplegia (Euro-Collins solution) was infused in the main
pulmonary artery and the heart-lung block was explanted.
The lung was stored for 1 hour in Euro-Collins solution at
4° C before implantation to mimic conditions during
clinical lung transplantation. In the recipient, a left tho-
racotomy was performed and the left lung was dissected
and removed. The preserved, transduced donor left lung
was then implanted orthotopically into the recipient by
anastomosing the pulmonary vein and artery. The lung
was reperfused, after which the bronchus was anasto-
mosed. All anastomoses were performed with 10-0 mono-
filament sutures. The chest wall was closed with a small
chest tube in situ, which was removed during recovery
from anesthesia.
Lung retrieval and histochemical analysis. Seven days
after transplantation, native and transplanted lung,
spleen, kidney, and liver were harvested. Cross sections
from the midsection of the organs were embedded in
optimal cutting temperature (OCT compound) and snap
frozen in liquid nitrogen. Five 5 mm thick cryostat sections
were cut at 25 mm intervals. The specimens were fixed in
1.25% glutaraldehyde for 10 minutes at 4° C and rinsed
three times with phosphate-buffered saline (PBS) solu-
tion. The sections were then stained in a solution
of 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-
Gal); Boehringer Mannheim Corp., Indianapolis, Ind.) for
4 hours at 37° C. The X-Gal–stained specimens were then
rinsed in PBS and counterstained with eosin. Blue cells
indicated the presence of b-gal expression. Adjacent slides
were stained with hematoxylin and eosin for routine
histopathologic examination.
The distribution of transgene expression was evaluated
by an observer blinded to the origin of the slides, exam-
ining X-Gal staining in the lung by cell type (pneumocytes,
macrophages, endothelial and airway epithelial cells).
Transgene expression was quantified using the following
scoring system: 0% of cells staining 5 0, 1% to 25%
staining 5 1, 26% to 50% staining 5 2, 51% to 75%
staining 5 3, and .75% staining 5 4, and staining
intensity as pale (51) or dark (52). Five slides in each
animal were evaluated and the mean calculated. The
number of transduced cells represent the average of all
animals in the respective group.
Statistical analysis. Staining scores are expressed as
mean and standard error of the mean. The Kruskal-Wallis
test followed by individual Wilcoxon rank sum test was
used to evaluate differences between the groups.10 A p
value of less than 0.05 was considered significant.
Results
Mortality. The perioperative mortality in the
study was 20%. Only surviving animals were in-
cluded in the study.
Distribution of transgene expression. Transgene
expression was detected in transduced, transplanted
lungs at a level and intensity outlined in Table I.
Pneumocytes were the most frequently stained cell
type with up to 80% of the cells staining in a
particular section, followed by alveolar macro-
phages (Table I). Transgene expression was demon-
strated in small numbers of endothelial and bron-
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chial epithelial cells. b-Gal was not detected in the
control group (Fig. 1, a).
Effect of dose of vector. Two of five transplanted
lungs in the 108 group expressed b-gal but with a
limited distribution and intensity (Fig. 1, b). b-Gal
expression was detected in all six transplanted lungs
in the 109 group (Fig. 1, c). In the 1010 group, five of
six transplanted lungs expressed b-gal (Fig. 1, d). In
pneumocytes (Fig. 2), a significant difference in
staining number score was observed between the 108
group and the 109 and 1010 groups with Kruskal-
Wallis test (overall p value 0.04) followed by indi-
vidual Wilcoxon rank sum test (p 5 0.03 and p 5
0.04, respectively). After Bonferroni adjustment, the
p values reached borderline significance (p 5 0.06
and p 5 0.09, respectively).
Expression in distant organs. To assess expres-
sion in distant organs X-Gal staining was performed
Fig. 1. Sections of transplanted lung from the control group (a), the 108 pfu/ml group (b), the 109 pfu/ml
group (c), and the 1010 pfu/ml group (d). b-Galactosidase expression is indicated by the blue-stained cells.
Table I. Staining number and intensity scores (mean 6 SEM) for different cell types in the control group and
in the 108, 109 and 1010 pfu/ml groups
Controls 108 109 1010
Number Intensity Number Intensity Number Intensity Number Intensity
Pneumocytes 0 0 0.2 6 0.2 0.2 6 0.2 1.7 6 0.5 1.3 6 0.3 1.7 6 0.5 1.3 6 0.3
Endothelial cells 0 0 0 0 0 0 0.2 6 0.2 0.2 6 0.2
Airway epithelial cells 0 0 0 0 0.03 6 0.03 0.03 6 0.03 0 0
Macrophages 0 0 0 0 0.2 6 0.2 0.2 6 0.2 0.4 6 0.2 0.3 6 0.2
SEM, Standard error of the mean.
Transgene expression was quantified using the following scoring system: 0% of cells staining 5 0, 1% to 25% staining 5 1, 26% to 50% staining 5 2, 51%
to 75% staining 5 3, and .75% staining 5 4, and staining intensity as pale (5 1) or dark (5 2).
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in native lung, spleen, liver, and kidney of trans-
planted animals. We were unable to detect trans-
gene expression in any of the tissues examined.
Vector toxicity. Histopathologic examination of
hematoxylin and eosin–stained lung slides cut im-
mediately adjacent to the slides stained for X-Gal,
showed signs of mild, patchy, chronic inflammation
(lymphocytes and macrophages) in three animals in
the 1010 group and in one animal in the 109 group,
whereas in the other animals no inflammation was
seen. In the 108 group and in the control group no
lungs showed any inflammation. No correlation be-
tween the efficiency of gene transfer and the pres-
ence of inflammation was found.
Discussion
Transplantation, with the opportunity to pretreat
the donor organ at the time of harvest, provides a
unique opportunity for genetic modification of the
graft. In the future, introduction of genes encoding
for biologically active compounds, which influence
the immunologic or physiologic reactivity of the
bronchial airways and vessels, may offer a novel
approach to modify pathologic processes in the
transplanted lung. In this study we show for the first
time that efficient gene transfer to the transplanted
lung by way of the airways is feasible by use of an
adenovirus vector.
Recently, Chapelier and colleagues5 reported ad-
enovirus-mediated gene transfer to transplanted
lungs in pigs with pulmonary artery administration
of a high concentration of vector (2 3 1011 pfu/ml).5
This method resulted in a rather low transduction
rate, which is in accordance with previous nontrans-
plant studies that used pulmonary artery adminis-
tration.11, 12 Even though comparisons between dif-
ferent species are problematic, this study indicates
that airway administration may increase the effi-
ciency of adenovirus-mediated gene transfer to the
transplanted lung. However, transduction in this
study was restricted mainly to pneumocytes, which
may limit the use of a solution administered by way
of the airways if the disease target is predominantly
in the airways. In contrast, Janssens and colleagues8
reported efficient gene transfer after aerosolized
delivery of an adenoviral vector to all pulmonary
cells, including airway epithelial cells.
In these experiments we observed considerable
variability in the efficiency of gene transfer. Indeed,
in one animal in the group transgene expression was
not detected. We are unclear as to the reason for
this observation but believe that it is due to biologic
variability of gene transfer. It is obviously, however,
an issue that needs to be addressed by further
studies.
In this study viral transduction appeared to be
more effective at higher viral concentrations (109
and 1010 pfu/ml compared with 108 pfu/ml). How-
Fig. 2. Staining number scores in pneumocytes (mean 6 SEM) in the 108 pfu/ml group, the l09 pfu/ml
group, and the 1010 pfu/ml group. A significant difference can be observed between the 108 pfu/ml group
and the l09 and the 1010 pfu/ml group (p 5 0.03 and p 5 0.04, respectively).
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ever, no difference was observed between 109 and
1010 pfu/ml, suggesting that no advantage may be
found to using higher doses than 109 pfu/ml. Use of
the lowest effective dose of vector may be important
in reducing viral toxicity. Because the virus solution
is left in the lung after transplantation, virus may
enter the systemic circulation at that time. However,
we could not detect transgene expression in liver,
kidney, or spleen 1 week after transplantation with
these doses of vector. This does not, however,
exclude low levels of transgene expression because
b-gal staining may not be sensitive enough for this
purpose.
We have previously described gene transfer to the
transplanted heart.4 In contrast with the observa-
tions in that study, transgene expression appeared to
be higher in the transplanted lung with the same
concentrations of vector. This may be a result of a
higher affinity of adenovirus for pneumocytes than
myocytes or may result from the technique of ad-
ministration or a combination of both. The bron-
chial administration route allows transduction at
normal body temperature in a perfused, oxygenated
lung. In contrast, gene transfer to the transplanted
heart during cold ischemia may be less efficient.
Data are conflicting as to whether adenovirus-me-
diated gene transfer is temperature dependent.
Gene transfer to endothelial cells in vitro was re-
ported by Chapelier and colleagues5 to be better at
37° C compared with 10° C, whereas Merrick and
colleagues13 concluded that gene transfer to endo-
thelial cells in cell and organ cultures was not
influenced by temperature. Csete and colleagues14
reported a transduction rate of up to 80% of hepa-
tocytes in liver grafts transducted at 4° C, indicating
that adenoviral affinity may be more important than
temperature. No study analyzing the effect of tem-
perature dependence in vivo has been reported and
will be difficult to perform in the setting of trans-
plantation because the donor organs require cold
storage for preservation during the inevitable isch-
emia before implantation.
The efficiency of adenoviral-mediated gene trans-
fer to airway epithelial cells is unclear. It has been
reported that adenovirus has a natural affinity for
bronchial epithelial cells15 and that regenerating
epithelial cells are a preferential target for adenovi-
rus.16 In contrast, a study from Zabner and col-
leagues17 indicates that adenoviral-mediated gene
transfer to differentiated bronchial cells is extremely
inefficient. In this study rare bronchial and bron-
chiolar epithelial cells expressed b-gal, which may
be due to the delivery method. After the virus was
delivered to the bronchus, the lung was ventilated
for 5 minutes and this may have resulted in delivery
of the vector predominantly to the alveoli. There-
fore the dwell time in the airways may have been too
brief to result in efficient gene transfer to airway
epithelial cells.
The lack of gene expression to airway epithelium
suggests that additional alternative methods of de-
livery may need to be explored to treat or prevent
pathologic processes in the bronchus and bronchi-
oles. Obliterative bronchiolitis is the major cause of
mortality after lung transplantation, with an inci-
dence of 45% to 55% in patients surviving more
than 1 year.1 The hope would be in the future that
prevention or treatment of obliterative bronchiolitis
by delivery of genes encoding for antiproliferative
substances may be possible in the setting of lung
transplantation.
In summary, this study shows that adenovirus-
mediated gene transfer by way of the airways to the
transplanted lung is feasible. This may offer new
possibilities to modify pathologic processes in the
transplanted lung.
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